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ABSTRACT
The tumor suppressor p53 is the most commonly
mutated gene in human cancers. Active p53 is able
to stimulate the transcription of a variety of genes
including the pro-apoptotic gene bax, as well as
p21, a cell cycle regulator. In this study we produced
novel zinc ®nger transcription factors that would
selectively increase the expression of bax, but not
of other p53 targets. Reporter gene assays in p53-
negative Saos-2 cells showed that the novel zinc
®nger proteins stimulated transcription driven by a
minimal bax promoter, but not that driven by a
minimal p21 promoter. Moreover, electromobility
shift assays demonstrated that the novel transcrip-
tion factors could bind the bax promoter sequence
with high af®nity and selectivity. Expression of a
®ve zinc ®nger protein (5ZFAV) in COS-7 cells
resulted in an increase in Bax protein levels, indicat-
ing that this novel transcription factor could act on
endogenous gene expression. Expression of 5ZFAV
also drastically reduced Saos-2 cell survival; this
effect could be reversed by the general caspase
inhibitor B-D-FMK. These data suggest that 5ZFAV
is able to induce apoptosis through increased Bax
expression. Further, while expression of 5ZFAV in
p53-de®cient Saos-2 cells reduced cell survival,
there was little effect on U-2 OS cells which have
wild-type p53. Thus the selective induction of the
pro-apoptotic bax gene may be a valuable adjunct to
cancer chemotherapy by diminishing survival of
p53-de®cient tumor cells.
INTRODUCTION
The tumor suppressor p53 plays a key role in the cellular
response to stress signals such as DNA damage, activated
oncogenes, hypoxia or nucleotide depletion (1,2). Normal
cells contain low levels of unstable and latent p53 wild-type
protein. Upon activation and stabilization by post-translational
modi®cations, p53 can function as a sequence-speci®c tran-
scription factor. Activated p53 is able to regulate a number of
target genes, including p21 (waf1/cip1) and bax (3). Increased
transcription of the p21 gene leads to inactivation of cyclin-
dependent kinases, which then results in G1 cell cycle arrest
(4), while p53-mediated expression of the Bcl-2 family
member Bax leads to apoptosis (5).
It has been reported that activation and/or overexpression of
Bax results in its translocation to the outer mitochondrial
membrane (6), where Bax induces the release of cytochrome c
(7). Cytochrome c forms a complex with Apaf-1 and
procaspase 9, which leads to the activation of the downstream
caspase cascade, eventually resulting in apoptosis (5,8±10).
The pro-apoptotic effects of Bax can be inhibited by the anti-
apoptotic Bcl-2 family members (Bcl-2 and Bcl-XL), and it is
commonly assumed that the ratio of pro- to anti-apoptotic
Bcl-2 family member proteins determines the fate of the cell
(11). Thus, in¯uencing the ratio of pro- to anti-apoptotic Bcl-2
family member proteins by selective transcription of the bax
gene should drive cells into apoptosis. This possibility
identi®es the bax gene as an interesting therapeutic target.
The p53 gene product is lost or inactivated by mutation in
over 50% of cancers (12). This tends to make cancer cells
refractory to chemotherapeutic agents, since p53 negative
cells fail to induce bax, as well as other p53-regulated pro-
apoptotic genes (13,14). These observations underlie recent
approaches using transfection of bax with the goal of driving
cancer cells into programmed cell death (15,16). As an
alternative approach, in the studies described below, we use
novel designed trancription factors to selectively regulate the
expression of bax.
The design of arti®cial transcription factors to control the
expression of targeted genes represents a rapidly growing area
of research. Transcription factors are generally of modular
structure and contain a DNA binding domain as well as a
trans-regulating domain. The Cys2-His2 type of zinc ®nger
(Zif) provides a particularly valuable tool for creating novel
transcription factors with modi®ed DNA binding speci®cities,
since Zifs can function as semi-autonomous modules (17).
Several groups have used phage display strategies to select
novel zinc ®ngers (18±21), while our laboratory has identi®ed
zinc ®ngers with novel DNA binding abilities by using a yeast
one hybrid approach (22). This strategy was used to develop
zinc ®nger peptides that bind selectively to the MDR1
promoter, leading to the design of a novel repressor able to
inhibit the transcription of the chromosomal MDR1 gene and
modulate tumor cell drug resistance (23,24).
In the present study we designed novel transcription factors
to selectively regulate expression of the bax gene. We used
DNA binding domains comprised of three or ®ve Zifs, which
were based on the zinc ®ngers from the mouse transcription
factor Zif268 (25). The Zifs were coupled to the VP16
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transactivation domain (26). The novel transcription factors
were able to increase transcription of a reporter gene driven by
a truncated arti®cial bax promoter, but not a reporter gene
driven by a truncated p21 promoter. Transiently transfected
COS-7 cells carrying a novel ®ve zinc ®nger transcription
factor showed an increased Bax expression. Transfection of
this factor also resulted in a drastic reduction of survival of
p53-de®cient Saos-2 cells; this effect could be reversed by the
addition of caspase inhibitors. These data suggest that the
designed zinc ®nger proteins are capable of driving Saos-2




All protein-expressing plasmids used in this study are based on
the mammalian expression vector pcDNA3.1(±)/Myc-HisA
(Stratagene, La Jolla, CA). As previously described (23), we
cloned the nuclear localization sequence (NLS) from the TAT
protein [amino acids 37±60 (27)] into XbaI±EcoRI restricted
pcDNA3.1. Using the restriction enzymes EcoRI±KpnI we
added the zinc ®nger sequences in frame downstream of the
NLS. In the ®nal step we cloned the VP16 transactivation
domain [amino acids 411±490 (26)] into a KpnI±HindIII
restriction site C-terminal to the zinc ®nger coding regions
(Fig. 1A). The resulting plasmids were named pcZFAV,
pcZF123V, which code for 3-Zif proteins, and pc5ZFAV,
which codes for a 5-Zif protein; all expressed proteins are
C-terminal Myc and His tagged. The plasmid pCMV-p53 was
purchased from Clontech (Palo Alto, CA), and a Bax
expressing plasmid was purchased from Upstate
Biotechnology (Lake Placid, NY). Reporter plasmids are
based on the pFR-Luc plasmid (Stragene, La Jolla, CA). The
®ve yeast Gal4 binding sites upstream of the luciferase gene
were excised with HindIII/KpnI and replaced by a multiple
cloning site (MCS) containing BglII, PstI, AgeI, PvuII,
HindIII, a TATATAA-box and KpnI. Inserting the MCS into
pFR-Luc resulted in the loss of the original HindIII site. Either
two bax [two times ±489 to ±449: TGGGCTCACAAG-
TTAGAGACAAGCCTGGGCGTGGGCTATAT; (28)] or
two p21 [two times ±2300 to ±2331: CAGGAACATGT-
CCCAACATGTTGAGCTCTGGC; (29)] promoter regions,
both containing consensus p53 binding sites (underlined),
were cloned into the BglII/HindIII sites of the MCS. The
resulting vectors were named pFR*-2bax and pFR*-2p21. The
MCS, as well as the promoter regions, were obtained by
annealing two primers coding for these sequences. Primers
were obtained from the Nucleic Acids Core Facility
(Lineberger Comprehensive Cancer Center, UNC).
Cells
Escherichia coli DH5a competent cells were obtained from
Life Technologies (Gaithersburg, MD). The p53-de®cient
human osteosarcoma Saos-2 cell line, the wild-type p53-
containing human osteosarcoma U-2 OS cell line, and the
monkey kidney COS-7 cell line were obtained from the
Lineberger Comprehensive Cancer Center (University of
North Carolina). Saos-2 and U-2 OS cells were cultured in
McCoy's 5A medium with L-glutamine and COS-7 cells were
cultured in Dulbecco's Modi®ed Eagle's Medium. Both media
were obtained from Life Technologies (Geithersburg, MD)
and, if not otherwise described, were used supplemented with
10% fetal bovine serum (FBS).
Transient transfection
Saos-2 or U-2 OS cells were transiently transfected using
LipofectAMINEÔ reagent (Life Technologies, Geithersburg,
MD) and COS-7 cells were transiently transfected using
SuperFectÔ reagent (Qiagen Inc., Valencia, CA), both
according to the manufacturer's recommendation.
CD4 enrichment
Saos-2 and U-2 OS cells were plated in 100 mm dishes (1.6 3
106 cells/dish) and transiently co-transfected with a CD4-
expressing plasmid (4 mg) and 2 mg [0.255 ng/mm2 plate area]
plasmids coding for 5ZFAV or Bax or the empty vector. The
cells were harvested 15 h after transfection and selected for
transfected cells with magnetic anti-CD4 Dynabeads M-450
(Dynal ASA, Oslo, Norway) according to the manufacturer's
recommendation. Transfected cells were lysed in modi®ed
RIPA buffer and used in western blot experiments.
Western blotting
Transfected cells were lysed in modi®ed RIPA buffer (24). In
some cases nuclear extracts were obtained with NE-PERÔ
nuclear and cytoplasmic extraction reagents (PIERCE,
Rockford, IL) according to the manufacturer's recommenda-
tion. Lysates and nuclear extracts were resolved by
SDS±PAGE and proteins detected by western blotting as
described (24). Expressed zinc ®nger proteins were detected
by using a mouse monoclonal anti c-myc antibody 9E10
(BABCO, Richmond, CA) at a dilution of 1:2000. The
secondary antibody was a peroxidase-conjugated goat anti
mouse IgG antibody (Calbiochem, San Diego, CA) at a
dilution of 1:5000. Bax proteins were detected using a rabbit
polyclonal anti bax antibody (Upstate Biotechnology, Lake
Placid, NY) at a dilution of 1:700. Actin was detected by using
a rabbit anti actin antibody (Sigma-Aldrich Co., St Louis,
MO), at a dilution of 1:7000. The secondary antibody was a
peroxidase-conjugated goat anti rabbit IgG antibody
(Calbiochem, San Diego, CA) at a dilution of 1:5000.
Signals were detected by enhanced chemiluminescence
(ECL kit, Amersham, Arlington Heights, IL) using X-ray
®lms (Denville Scienti®c Inc., Metuchen, NJ). Densitometry
data were collected with the Fluor-SÔ MultiImager (Bio-Rad,
Philadelphia, PA) and analyzed with Quantity One software
(Bio-Rad, Philadelphia, PA).
Electromobility shift assays
Proteins were expressed using the TNTâ quick coupled
transcription/ translation system from Promega (Madison,WI).
Double-stranded (ds) DNA sequences were produced by
annealing complementary oligonucleotides containing zinc
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CGTAGTGAGCT GAT; 3¢Zif268BS ATCAGCTCACTA-
CGCCCA(GCTTCACCTCCT)]. For each oligonucleotide
pair we designed a short version (without the nucleotides in
the brackets) and a long version (with the nucleotides in the
brackets) of the 3¢ primer. Radiolabeled ds oligonucleotides
were obtained from complexes using the short 3¢-oligonucleo-
tides by ®ll-in reactions with [a-32P]dCTP and Klenow
Enzyme (Roche Diagnostics, Indianapolis, IN). Annealing of
the long versions of the synthetic oligonucleotides resulted in
unlabeled ds oligonucleotides. All oligonucleotides were
purchased from the Nucleic Acids Core Facility (Lineberger
Comprehensive Cancer Center, UNC). Proteins (5 ml samples)
from the TNTâ Quick reaction were pre-incubated at room
temperature with the non-speci®c competitor poly dI-dC
(1 mg/reaction) and PMSF (1 mM). After 10 min labeled probe
(with or without unlabeled speci®c competitor) was added.
The reactions were incubated for 20 min in binding buffer
containing 50 mM Tris pH 7.6, 50% glycerol, 5 mM DTT and
2.5 mM EDTA. The samples were loaded on a 5%
polyacrylamide gel (50% glycerol) and run at 150 V in 13
TGE buffer (Tris, glycine, EDTA) at room temperature for 2 h.
The gel was dried and exposed to X-ray ®lm.
Dual luciferase reporter assay
Saos-2 cells were plated in 12 well plates (1.3 3 105 cells/
well) and 24 h later were transiently co-transfected with
0.33 mg (0.25 ng/mm2 plate area) protein expressing plasmids
(pcZFAV, pc5ZFAV or pCMV-p53) or with pcDNA3.1, and
with 1 mg reporter plasmid (pFR*-2bax or pFR*-2p21) and
0.1 mg renilla luciferase plasmid pRL-TK (Promega, Madison,
WI) for 4 h. Cells were washed and incubated in 1% FBS-
containing medium. Luciferase activities were determined
using the dual-luciferaseÔ reporter assay system (Promega,
Madison, WI) 18±20 h after transfection. Renilla luciferase
activities were used as an internal control to normalize
obtained activities. Measurements were performed on a
Monolight 2010 instrument (Analytical Luminescence
Laboratory, San Diego, CA).
Cells survival assays
Saos-2 or U-2 OS cells were plated in 60 mm dishes (8 3 105
cells/dish) and 24 h later were transiently co-transfected with a
b-galactosidase-expressing plasmid (2 mg) and a protein-
expressing plasmid [1 mg (0.35 ng/mm2 plate area) of
pcZFAV, pc5ZFAV, pCMV-p53 or a Bax-expressing plas-
mid]. After transfection, cells were incubated in 1% FBS-
containing medium. Caspase inhibitor [B-D-FMK (Enzyme
Systems Products, Livermore, CA)] was used at a concentra-
tion of 40 mM and added to the medium 0 and 12 h after
transfection. At 24 h post-transfection cells were washed,
®xed and stained for b-galactosidase activity. Blue
(b-galactosidase positive) cells were counted using a gridded
60 mm dish and a tissue culture microscope. The number of
blue cells that could be observed in transfections with
b-galactosidase plus `empty' vector controls was taken as
100% and was used for normalization.
Enzymatic cell survival assay
Saos-2 or U-2 OS cells were plated in 12 well plates (7 3 104
cells/well) and 24 h later were transiently co-transfected with
0.08 mg plasmids (0.06 ng/mm2 plate area) coding for the
various proteins indicated or the `empty' vector and with a
b-galactosidase plasmid (0.5 mg). After transfection, cells
were washed and incubated in FBS-containing medium.
b-Galactosidase activities were determined 96 h after
transfection using the b-galactosidase Enzyme Assay System
(Promega, Madison, WI). Measurements were performed on a
Universal Microplate Reader ELX800 (Bio-Tek Instruments,
Winooski, VT) at 405 nm. The average absorbance with
b-galactosidase plasmid and pcDNA3.1 empty vector was set
as 100% for normalization.
RESULTS
Construction and expression of novel Zif transcription
factors
In examining the bax promoter we detected consensus binding
sites for zinc ®ngers one (ZF1) and two (ZF2) of the native
Zif268 transcription factor in close proximity to the p53
consensus binding site; the promoters of other p53 responsive
genes, such as p21, lack such sites. In addition, previous
screening in yeast for Zifs with novel DNA-recognition
capabilities (23) yielded two novel Zifs termed ZF3* and
ZF1* that could recognize additional sites overlapping or
adjacent to the bax p53 consensus site; these novel zinc ®ngers
were based on Zif268, but had altered residues at critical DNA
binding positions. Using ZF3*, which binds the nucleotide
triplet `GCC', as well as the native ZF1 and ZF2 modules, we
constructed a three zinc ®nger protein termed ZFAV. This
novel transcription factor is designed to bind the DNA
sequence `GCCTGGGCG', which overlaps with the bax
promoter p53 consensus binding site (Fig. 1A). To seek
stronger binding to the bax promoter, we added two extra zinc
®ngers N-terminal to the ZFAV DNA-binding modules; these
were native ZF2, and ZF1* which was selected to bind the
`GCT' nucleotide triplet. This resulted in a ®ve zinc ®nger
transcription factor that we termed 5ZFAV that was designed
to bind the DNA sequence `GCCTGGGCGTGGGCT' which
overlaps the p53 binding site. Both ZFAV and 5ZFAV
contained a NLS and the mammalian trans-activator domain
of VP16 (Fig. 1A). As a control we constructed a similar
transcription factor carrying wild-type zinc ®ngers one (ZF1),
two (ZF2) and three (ZF3) of Zif268; the resulting plasmid
was named pcZF123V.
The plasmids coding for the various novel transcription
factors were transiently transfected into p53 de®cient Saos-2
cells and expression as well as nuclear localization was
detected by western blot analysis. Immunoblotting showed a
strong expression of the three zinc ®nger (ZFAV, ZF123V)
and ®ve zinc ®nger (5ZFAV) proteins in the nucleus of Saos-2
cells (Fig. 1B).
Selective activation of a minimal Bax promoter by the
novel transcription factors
To test the effects of the novel zinc ®nger proteins on the p53
binding site containing bax or p21 promoters we performed
Dual Luciferase assays (Promega). Human p53 de®cient Saos-
2 cells were cotransfected with plasmids coding for the
transcription factors and with the reporter plasmids pFR*-
2bax or pFR*-2p21. The novel zinc ®nger proteins ZFAV (2)
and 5ZFAV (3) were able to increase expression of the
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luciferase gene under the control of the truncated bax
promoter 9- to 10-fold (Fig. 2). In comparison, these proteins
had no effect on luciferase gene expression regulated by the
truncated p21 promoter. Both ZFAV (2) and 5ZFAV (3)
displayed only modest activation of the bax reporter as
compared with the effect of native p53 (4); however, the effect
of the novel factors was very selective in favoring bax over
p21, whereas p53 (4) activated both reporters (Fig. 2).
ZFAV and 5ZFAV bind to bax promoter sequences
We examined the ability of the novel transcription factors to
bind to sequences in the bax promoter using electromobility
shift assays (EMSAs) (Fig. 3). We expressed ZFAV, 5ZFAV
and ZF123V using an in vitro transcription/translation system.
ZF123V, carrying the wild-type zinc ®ngers of the transcrip-
tion factor Zif268, was used as a control, since the binding
af®nities are well known (30). ZFAV and 5ZFAV bound to the
bax ds oligonucleotide (Fig. 3A, lanes 10 and 15), and the
binding could be competed by the addition of increasing
amounts of unlabeled bax oligonucleotide (lanes 11±13 and
16±18). ZF123V did not bind the bax sequence (lane 20), but
rather bound the consensus Zif268 binding sequence (lane 1)
and this binding could also be competed by increasing
amounts of unlabeled oligonucleotide (lanes 2±4). The
EMSAs also indicated the selective binding of ZFAV and
5ZFAV to the bax but not to the p21 promoter sequences,
since the binding to the bax sequence could be competed by
unlabeled bax but not p21 competitor oligonucleotides
(Fig. 3B). The selectivity of 5ZFAV for its targeted sequence
was also con®rmed by the fact that bax competitor
oligonucleotides blocked binding of 5ZFAV to the bax
sequence while zif268BS competitor oligonucleotides had
only a slight effect (Fig. 3C).
5ZFAV induces Bax expression in COS-7 cells
Since Saos-2 cells have very low transfection and protein
expression ef®ciency, we used COS-7 cells to test whether
ZFAV or 5ZFAV could up-regulate expression of endogenous
Bax. Constructs expressing ZFAV, 5ZFAV or Bax proteins
were transiently transfected into the cells, and whole cell
lysates were harvested after 24 h. The lysates were
immunoblotted with an anti Bax antibody. These experiments
showed an increase of Bax expression in cells carrying the ®ve
zinc ®nger protein 5ZFAV as compared with control cells
tranfected with empty vector (Fig. 4). As a positive control we
transfected COS-7 cells with various amounts of a Bax-
expressing plasmid; this also led to increased Bax protein
levels. Transfection of 5ZFAV did not affect levels of p21
protein in these experiments (not shown). Thus 5ZFAV
selectively induced a moderate overexpression of Bax in
COS-7 cells. In similar experiments in Saos-2 cells we were
not able to detect increased Bax expression by western
blotting of whole cell lysates (even with transfection of Bax
vector) presumably because of poor transfection ef®ciency
and low levels of protein production (data not shown).
5ZFAV causes caspase-dependent cell death
Since the novel transcription factor 5ZFAV could up-regulate
Bax expression, we were interested in determining whether it
could cause apoptosis. Here we used p53-de®cient Saos-2
cells so that the effects of 5ZFAV could be examined
independently of p53. Thus cells were transfected with a
b-galactosidase plasmid as a marker for transfection, and co-
transfected with vectors expressing ZFAV, 5ZFAV, Bax or
p53, or with pcDNA3.1 `empty' vector as a control. In these
experiments (Fig. 5A) it was clear that Bax, p53 and 5ZFAV,
but not ZFAV, could dramatically reduce cell survival. This
effect was fully reversed by the general caspase inhibitor B-D-
FMK for the cases of Bax and 5ZFAV, but only partially
reversed for p53 (Fig. 5B). Thus the novel transcription
factor 5ZFAV reduces cell survival by a caspase-dependent
mechanism.
Figure 2. Transcriptional activities of ZFAV and 5ZFAV in Saos-2 cells.
Luciferase activities were measured 24 h after transfection and normalized
against renilla luciferase activities. Luciferase activities obtained with the
reporter vector pFR*-2p21 are in black bars and activities obtained with the
reporter vector pFR*-2bax are in gray bars. Normalized luciferase activities
obtained with cell lysate from cells transfected with the empty vector
pcDNA3.1 were set as one. The transfected plasmids were (1) pcDNA,
(2) ZFAV, (3) 5ZFAV, (4) p53.Figure 1. (A) Structure of the novel three (ZFAV) and ®ve (5ZFAV) zinc
®nger transcription factors binding to their cognate sites in the bax
promoter. ZF1 and ZF2 are wild-type zinc ®ngers of the transcription factor
Zif268. ZF1* and ZF3* are zinc ®ngers selected by screening combinatorial
libraries (22). VP16 is a trans-activation domain and NLS is a nuclear
localization sequence. The consensus p53 binding site is shown in the box
and the zinc ®nger binding sites are shown in bold. (B) Protein expression.
Saos-2 nuclear cell extracts were immunoblotted with anti-Myc (9E10)
antibody. The black arrows show the positions of the zinc ®nger proteins;
the gray arrowhead marks non-speci®c bands seen in controls.
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Effects of 5ZFAV are dependent on p53 status
The studies above suggest that the ®ve Zif transcription factor
can upregulate Bax levels and induce caspase-dependent cell
death. However, it is clear that the effects of 5ZFAV are
weaker than those of Bax itself or of p53. Thus it seemed
important to test the effects of 5ZFAV in cell lines that
possessed or lacked wild-type p53. As seen in Figure 6A, over-
expression of Bax led to impaired cell viability in both p53-
de®cient Saos-2 cells and p53 replete U-2 OS cells. However,
over-expression of 5ZFAV reduced the viability of Saos-2
cells but not U-2 OS cells. Thus the effects of 5ZFAV on cell
survival seems to depend on the p53 status of the cell. To
examine Bax expression levels we selected for transfected
cells with CD4 Dynabeads. In agreement with the cell survival
assay, pc5ZFAV transfected Saos2 cells, but not pc5ZFAV
transfected U-2 OS cells showed a modest but constant
increase in Bax expression compared with empty vector
transfected cells (Fig. 6B and C).
DISCUSSION
When p53 is up-regulated in response to DNA damage or to
other stresses, a complex cell regulatory network is entrained.
P53 increases expression of pro-apoptotic genes such as Bax
and Noxa (1,14), as well as cell cycle control genes such as
p21 (29), and genes involved in DNA repair (31). Thus the
ultimate outcome in terms of cell death versus cell cycle arrest
depends on the interplay of multiple genes downstream of p53
(32). In some cases it may be desirable to selectively regulate
one or more p53 target genes. In particular, the selective
Figure 3. Binding of ZFAV and 5ZFAV to bax ds oligonucleotides. (A) The three zinc ®nger proteins ZFAV, ZF123V and the ®ve zinc ®nger protein
5ZFAV were incubated with the indicated labeled dsDNA and the binding was competed by the addition of increasing amounts of unlabeled oligonucleotide
competitor. (B) The binding of ZFAV and 5ZFAV to the bax promoter was competed by increasing amounts of bax or p21 unlabeled oligonucleotide and in
(C) with increasing amounts of bax or zif268BS unlabeled oligonucleotide. The concentrations of radiolabeled probe in (A) were 1.7 pmol/ml for zif268BS
and 2.1 pmol/ml for bax. The concentrations of unlabeled competitor ranged from 0±346 pmol/ml for zif268BS, and 0±416 pmol/ml for bax. In (B) the
concentration of radiolabeled bax probe was 3.8 pmol/ml, while the ranges of unlabeled competitors were 0±1.54 nmol/ml for bax and 0±2.55 nmol/ml for
p21. In (C), 0.4 pmol/ml labeled bax was used, while the unlabeled competitors ranged from 0±174 pmol/ml bax and 0±174 pmol/ml zif268BS.
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up-regulation of pro-apoptotic genes in cancer cells could
result in enhanced effectiveness for chemotherapy agents.
Thus in this study we have described novel zinc-®nger
transcription factors that selectively activate the bax gene, but
not other p53 responsive genes, with p21 serving as a model.
The ZFAV and 5ZFAV proteins selectively activate a
minimal Bax promoter, but not a minimal p21 promoter,
although both share p53 consensus sites. Thus these novel Zif
transcription factors are selective. In terms of ef®cacy, ZFAV
and 5ZFAV are much weaker than native p53 in driving the
Bax promoter. However, this is not unexpected since p53
binds to its consensus sites as a tetramer and thus brings four
transactivating domains into play (33), while ZFAV and
5ZFAV are designed to bind as monomers. The selectivity of
ZFAV and 5ZFAV was con®rmed in EMSA where these
proteins were shown to bind to oligonucleotides re¯ecting the
bax promoter but not those re¯ecting the p21 promoter.
Surprisingly, there was only a modest difference in the binding
of 5ZFAV and ZFAV, despite the presence of two extra Zifs in
the former (data not shown). Interestingly, although ZFAV
and 5ZFAV behaved fairly similarly in in vitro binding assays
and in reporter gene assays, 5ZFAV was much more effective
in inducing Bax protein expression and in triggering cell
death. The basis for this difference is not clear at this time;
however, it is possible that 5ZFAV is more effective at
accessing chromosomal sites than is ZFAV.
A cell survival assay showed that the expression of 5ZFAV
in Saos-2 cells led to cell death. To test whether this was due to
apoptosis or to a general toxic effect we blocked caspase
activation by the addition of the general caspase inhibitor B-
D-FMK. It is known that overexpression and/or activation of
Bax leads to apoptosis via the activation of a caspase cascade,
and that inhibition of caspase activation blocks Bax-mediated
apoptosis (34). This was true in the present studies, since the
addition of B-D-FMK led to a complete inhibition of apoptosis
in Saos-2 cells ectopically overexpressing Bax. Since a similar
caspase inhibitor effect was observed for 5ZFAV-induced cell
death, this suggests that 5ZFAV causes a form of caspase-
dependent apoptosis. However, we have not yet extensively
Figure 5. Cell survival assay. (A) Co-transfected Saos-2 cells (b-galactosi-
dase plasmid plus plasmids coding for the various proteins indicated) were
®xed and stained for b-galactosidase activity. Blue cells per microscope
®eld were counted. The average number of blue cells in samples transfected
only with b-galactosidase plasmid and pcDNA3.1 empty vector was set as
100% for normalization. (B) Cell survival with a caspase inhibitor. Co-
transfected cells treated or untreated with the caspase inhibitor B-D-FMK
(200 nM) were ®xed and stained for b-galactosidase. The samples were nor-
malized as in (A). Transfection ef®ciency was ~10% in these assays.
Figure 6. Survival of Saos-2 versus U-2 OS cells. (A) Saos-2 or U-2 OS
cells were plated in 12 well plates (1.3 3 105 cells/well) and 24 h later
were transiently co-transfected with 0.08 mg plasmids (0.06 ng/mm2 plate
area) coding for the various proteins indicated or the `empty' vector and
with a b-galactosidase plasmid (0.5 mg). Cells were washed and incubated
in FBS-containing medium. b-Galactosidase activities were determined 96 h
after transfection. The average absorbance with b-galactosidase plasmid and
pcDNA3.1 empty vector was set as 100% for normalization. (B) Bax
expression. Co-transfected Saos-2 and U-2 OS cells (CD4-expressing
plasmid plus plasmids coding for the various proteins indicated) were CD4
enriched for transfected cells and their lysates were immunoblotted with
anti-Bax or anti-actin antibody. (C) Densitometry data were used to
determine the ratios of Bax to actin expression in cells carrying 5ZFAV,
Bax or empty vector pcDNA3.1. The Bax to actin ratio of empty vector
pcDNA3.1 transfected cells was set as one. Results represent the means and
standard errors of three experiments.
Figure 4. Bax expression in transiently transfected COS-7 cells. Whole cell
lysates of cells transfected with pCMV-p53, pcZFAV, pc5ZFAV,
pcDNA3.1 or a Bax expressing plasmid were immunoblotted with an anti-
Bax or anti-actin antibody. un = untransfected cells.
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characterized the cell death process in the 5ZFAV transfec-
tants. Regulation of apoptosis is complex (35), but clearly
enhanced Bax levels are likely to play a role in this process.
The development of bax-gene targeted novel transcription
factors might be a useful tool for selectively killing p53-
de®cient tumor cells. These novel transcription factors may
have an advantage over the reintroduction of wild-type p53
proteins, or functional active monomeric p53 proteins, into
p53 mutated cancer cells, since mutated p53 proteins
frequently bind to wild-type p53, thus causing dominant
negative effects (36,37). Although Bax has a role in tumor cell
death (15,38), the biology of Bax induced cell death is quite
complicated (39). Simple transfection of Bax or other pro-
apoptotic proteins would not seem to offer any selectivity
between normal cells and p53-de®cient tumor cells. However,
5ZFAV, the novel bax-promoter targeted transcription factor,
seems to be more effective in p53-de®cient Saos-2 cells than
in U-2 OS cells that have wild-type p53. Since 5ZFAV is
a relatively weak transactivator compared with p53, its
bax-selective effects may be overcome by the presence of
wild-type p53. This may lead to a balanced expression of pro-
and anti-apoptotic genes in p53-replete cells. Thus 5ZFAV
might be considered a prototype for novel transcription factors
that act preferentially in p53 de®cient tumor cells rather than
normal cells having wild-type p53.
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